Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

“Listeria-Derived ActA Is An Effective Adjuvant for Primary and Metastatic Tumor Immunotherapy.”

In collaborative research out of the laboratories of Advaxis and the company’s scientific founder, Dr. Yvonne Paterson, at the University of Pennsylvania, it was found that ActA, either fused to an antigen and delivered with a live, attenuated Listeria vaccine or as a mixture with an antigen and not secreted by Listeria, resulted in a therapeutic immune response against TC-1 tumor cells. Moreover, it was found that the adjuvant actions of ActA stimulated immunity in the presence of immune tolerance, enabling a therapeutic response in animals whose immune systems were fatigued and ineffective against the target antigen.

For further details, these findings can be found in the scientific journal, “Cancer Immunology and Immunotherapy” in a soon to be published research paper titled, “Listeria-Derived ActA Is An Effective Adjuvant for Primary and Metastatic Tumor Immunotherapy.” The current online version can be found on Pubmed.Gov.